Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of February 2021, with the report dated February 8, 2021. The registrant is a foreign private issuer based in Jerusalem, Israel, filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The primary material change disclosed is a corporate governance update. On February 7, 2021, the Board of Directors approved the appointment of Mr. Amir Reichman, the Company's Chief Executive Officer, as a member of the Board of Directors. Mr. Reichman will serve until the next Annual General Meeting of shareholders.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the board appointment and incorporates the report by reference into the Company's Registration Statements on Form F-3 and Form S-8.
Investor Verification Checklist
- Verify the correct registrant name is BiondVax Pharmaceuticals Ltd., not Scinai Immunotherapeutics Ltd.
- Confirm the effective date of Mr. Amir Reichman's board appointment (February 7, 2021).
- Review the referenced Registration Statements (Form F-3 No. 333-240189 and Form S-8 No. 333-239344) for broader context.
- Note that no financial performance data is included in this specific filing.